サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1547784

静注用免疫グロブリンの世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測

Global Intravenous Immunoglobulin Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日
ページ情報
英文 128 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
静注用免疫グロブリンの世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測
出版日: 2024年07月01日
発行: Value Market Research
ページ情報: 英文 128 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

静注用免疫グロブリン市場の世界需要は、2023年の133億米ドルから2032年には270億米ドル近くの市場規模に達すると推定され、調査期間2024～2032年のCAGRは8.19%です。

静注用免疫グロブリン（IVIG）は、抗体欠乏症患者の治療に役立つ治療法です。IVIGは、何千人もの健康な人々の血漿から免疫グロブリン（抗体）を作り、感染症と闘う血液製剤です。免疫グロブリンは血漿細胞から産生される糖タンパク質です。IVIGは血漿から調製されるため、高度に精製されており、血液を介して感染症を発症する可能性は極めて低いです。この治療法は、川崎病、ループス、ギラン・バレー症候群、筋炎、慢性炎症性脱髄性多発神経炎（CIDP）、免疫性血小板減少症などの免疫不全など、多くの疾患の治療に役立っています。これに加えて、多発性硬化症や重症筋無力症などの神経疾患の治療にも使用されます。

市場力学

世界の静注用免疫グロブリン市場は、高齢者人口の増加、免疫不全疾患の高い有病率、血友病患者の増加、IVIG治療の受け入れ拡大、静注用免疫グロブリン投薬プロジェクトへの投資の増加などが主要要因となっています。免疫不全疾患患者の増加が、静注用免疫グロブリン療法の需要を押し上げる主要要因です。米国アレルギー感染症研究所（NIAID）によると、200種類以上の原発性免疫不全症（PIDD）があり、米国では約50万人がこのようなPIDDSに苦しんでいます。

調査レポートは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、静注用免疫グロブリンの世界市場における各セグメントを包括的に評価することもできます。静注用免疫グロブリン業界の成長と動向は、この調査に全体的なアプローチを記載しています。

市場セグメンテーション

静注用免疫グロブリン市場レポートのこのセクションでは、国別と地域別のセグメントに関する詳細なデータを提供し、それによって戦略家がそれぞれの製品またはサービスの対象層を特定する上で、今後の機会を支援します。

地域分析

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける静注用免疫グロブリン市場の現在と将来の需要を強調する地域展望をカバーしています。さらに、本レポートでは、著名な全地域における各用途セグメントの需要・推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 静注用免疫グロブリン-産業分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカー一覧
    • 主要原材料の価格動向
  • 潜在的バイヤー一覧
  • マーケティングチャネル
    • 直接マーケティング
    • 間接マーケティング
    • マーケティングチャネル発展動向

第5章 静注用免疫グロブリンの世界市場分析：用途別

  • 用途別概要
  • 実績データと予測データ
  • 用途別分析
  • 低ガンマグロブリン血症
  • CIPD
  • 免疫不全症
  • 先天性エイズ
  • 慢性リンパ性白血病
  • 重症筋無力症
  • 多巣性運動神経障害
  • 免疫不全症候群
  • 川崎病
  • ギランバレー症候群
  • その他

第6章 静注用免疫グロブリンの世界市場分析：流通チャネル別

  • 流通チャネル別概要
  • 実績データと予測データ
  • 流通チャネル別分析
  • 病院薬局
  • 専門薬局
  • その他

第7章 静注用免疫グロブリンの世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米：国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州：セグメント別
    • 欧州：国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他の欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋：セグメント別
    • アジア太平洋：国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他のアジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカ：セグメント別
    • ラテンアメリカ：国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他のラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカ：セグメント別
    • 中東・アフリカ：国別一覧
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他の中東・アフリカ

第8章 静注用免疫グロブリン企業の競合情勢

  • 静注用免疫グロブリン市場競争
  • 提携・協力・契約
  • 合併・買収
  • 新製品の上市
  • その他の開発

第9章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • Biotest AG
  • Baxter International Inc.
  • Octapharma AG
  • LFB Biotechnologies
  • Grifols SA
  • CSL Behring
  • China Biologics Products Inc.
  • Kedrion Biopharma
  • BDI Pharma Inc
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Application (USD MN)
  • Hypogammaglobulinemia Market Sales By Geography (USD MN)
  • CIPD Market Sales By Geography (USD MN)
  • Immunodeficiency Diseases Market Sales By Geography (USD MN)
  • Congenital AIDS Market Sales By Geography (USD MN)
  • Chronic Lymphocytic Leukemia Market Sales By Geography (USD MN)
  • Myasthenia Gravis Market Sales By Geography (USD MN)
  • Multifocal Motor Neuropathy Market Sales By Geography (USD MN)
  • ITP Market Sales By Geography (USD MN)
  • Kawasaki Disease Market Sales By Geography (USD MN)
  • Guillain-barre Syndrome Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacy Market Sales By Geography (USD MN)
  • Specialty Pharmacy Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Intravenous Immunoglobulin Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Intravenous Immunoglobulin Report
  • Market Research Process
  • Market Research Methodology
  • Global Intravenous Immunoglobulin Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Application
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Application (USD MN)
  • Hypogammaglobulinemia Market Sales By Geography (USD MN)
  • CIPD Market Sales By Geography (USD MN)
  • Immunodeficiency Diseases Market Sales By Geography (USD MN)
  • Congenital AIDS Market Sales By Geography (USD MN)
  • Chronic Lymphocytic Leukemia Market Sales By Geography (USD MN)
  • Myasthenia Gravis Market Sales By Geography (USD MN)
  • Multifocal Motor Neuropathy Market Sales By Geography (USD MN)
  • ITP Market Sales By Geography (USD MN)
  • Kawasaki Disease Market Sales By Geography (USD MN)
  • Guillain-barre Syndrome Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacy Market Sales By Geography (USD MN)
  • Specialty Pharmacy Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11213403

The global demand for Intravenous Immunoglobulin Market is presumed to reach the market size of nearly USD 27 Billion by 2032 from USD 13.3 Billion in 2023 with a CAGR of 8.19% under the study period 2024-2032.

Intravenous Immunoglobulin (IVIG) refers to a therapy that helps in treating patients with antibody deficiencies. It is a blood product made by immunoglobulin's (antibodies) from the plasma of thousands of healthy people to fight infections. Immunoglobulin's are glycoprotein's which are produced from the plasma cells. As IVIG is prepared from plasma, it is highly purified so the chances of developing a blood-borne infection are exceptionally low. This therapy helps in treating a large number of diseases such as kawasaki disease, lupus, guillain-barre syndrome, myositis, chronic inflammatory demyelinating polyneuropathy (CIDP) and also immune deficiencies such as immune thrombocytopenia. In addition to this it is also used for treating some neurological diseases such as multiple sclerosis or myasthenia gravis.

MARKET DYNAMICS

The global Intravenous Immunoglobulin Market is majorly driven by growing elderly population, high prevalence of immunodeficiency diseases, growing number of hemophilic patients, increase in acceptance of IVIG treatments and rising investment in intravenous immunoglobulin medication projects. Increasing number of patients with immunodeficiency disorders is the major factor boosting the demand of Intravenous Immunoglobulin therapy. As per National Institute of Allergy and Infectious diseases (NIAID) there are over 200 different forms of primary immune deficiency diseases (PIDDs) and around 500,000 people in the United States suffering from such PIDDS.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Intravenous Immunoglobulin. The growth and trends of Intravenous Immunoglobulin industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Intravenous Immunoglobulin market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Application

  • Hypogammaglobulinemia
  • CIPD
  • Immunodeficiency Diseases
  • Congenital AIDS
  • Chronic Lymphocytic Leukemia
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy
  • ITP
  • Kawasaki Disease
  • Guillain-barre Syndrome
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Specialty Pharmacy
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Intravenous Immunoglobulin market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Intravenous Immunoglobulin market include Biotest AG, Baxter International Inc., Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc., Kedrion Biopharma, BDI Pharma Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. INTRAVENOUS IMMUNOGLOBULIN - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Application
    • 3.7.2 Market Attractiveness Analysis By Distribution Channel
    • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET ANALYSIS BY APPLICATION

  • 5.1. Overview By Application
  • 5.2. Historical and Forecast Data
  • 5.3. Analysis By Application
  • 5.4. Hypogammaglobulinemia Historic and Forecast Sales By Regions
  • 5.5. CIPD Historic and Forecast Sales By Regions
  • 5.6. Immunodeficiency Diseases Historic and Forecast Sales By Regions
  • 5.7. Congenital AIDS Historic and Forecast Sales By Regions
  • 5.8. Chronic Lymphocytic Leukemia Historic and Forecast Sales By Regions
  • 5.9. Myasthenia Gravis Historic and Forecast Sales By Regions
  • 5.10. Multifocal Motor Neuropathy Historic and Forecast Sales By Regions
  • 5.11. ITP Historic and Forecast Sales By Regions
  • 5.12. Kawasaki Disease Historic and Forecast Sales By Regions
  • 5.13. Guillain-barre Syndrome Historic and Forecast Sales By Regions
  • 5.14. Others Historic and Forecast Sales By Regions

6. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 6.1. Overview By Distribution Channel
  • 6.2. Historical and Forecast Data
  • 6.3. Analysis By Distribution Channel
  • 6.4. Hospital Pharmacy Historic and Forecast Sales By Regions
  • 6.5. Specialty Pharmacy Historic and Forecast Sales By Regions
  • 6.6. Others Historic and Forecast Sales By Regions

7. GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET ANALYSIS BY GEOGRAPHY

  • 7.1. Regional Outlook
  • 7.2. Introduction
  • 7.3. North America Sales Analysis
    • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.3.2 North America By Segment Sales Analysis
    • 7.3.3 North America By Country Sales Analysis
    • 7.3.4 United States Sales Analysis
    • 7.3.5 Canada Sales Analysis
    • 7.3.6 Mexico Sales Analysis
  • 7.4. Europe Sales Analysis
    • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.4.2 Europe By Segment Sales Analysis
    • 7.4.3 Europe By Country Sales Analysis
    • 7.4.4 United Kingdom Sales Analysis
    • 7.4.5 France Sales Analysis
    • 7.4.6 Germany Sales Analysis
    • 7.4.7 Italy Sales Analysis
    • 7.4.8 Russia Sales Analysis
    • 7.4.9 Rest Of Europe Sales Analysis
  • 7.5. Asia Pacific Sales Analysis
    • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.5.2 Asia Pacific By Segment Sales Analysis
    • 7.5.3 Asia Pacific By Country Sales Analysis
    • 7.5.4 China Sales Analysis
    • 7.5.5 India Sales Analysis
    • 7.5.6 Japan Sales Analysis
    • 7.5.7 South Korea Sales Analysis
    • 7.5.8 Australia Sales Analysis
    • 7.5.9 South East Asia Sales Analysis
    • 7.5.10 Rest Of Asia Pacific Sales Analysis
  • 7.6. Latin America Sales Analysis
    • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.6.2 Latin America By Segment Sales Analysis
    • 7.6.3 Latin America By Country Sales Analysis
    • 7.6.4 Brazil Sales Analysis
    • 7.6.5 Argentina Sales Analysis
    • 7.6.6 Peru Sales Analysis
    • 7.6.7 Chile Sales Analysis
    • 7.6.8 Rest of Latin America Sales Analysis
  • 7.7. Middle East & Africa Sales Analysis
    • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 7.7.2 Middle East & Africa By Segment Sales Analysis
    • 7.7.3 Middle East & Africa By Country Sales Analysis
    • 7.7.4 Saudi Arabia Sales Analysis
    • 7.7.5 UAE Sales Analysis
    • 7.7.6 Israel Sales Analysis
    • 7.7.7 South Africa Sales Analysis
    • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE INTRAVENOUS IMMUNOGLOBULIN COMPANIES

  • 8.1. Intravenous Immunoglobulin Market Competition
  • 8.2. Partnership/Collaboration/Agreement
  • 8.3. Merger And Acquisitions
  • 8.4. New Product Launch
  • 8.5. Other Developments

9. COMPANY PROFILES OF INTRAVENOUS IMMUNOGLOBULIN INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Market Concentration Rate
  • 9.3. Biotest AG
    • 9.3.1 Company Overview
    • 9.3.2 Company Revenue
    • 9.3.3 Products
    • 9.3.4 Recent Developments
  • 9.4. Baxter International Inc.
    • 9.4.1 Company Overview
    • 9.4.2 Company Revenue
    • 9.4.3 Products
    • 9.4.4 Recent Developments
  • 9.5. Octapharma AG
    • 9.5.1 Company Overview
    • 9.5.2 Company Revenue
    • 9.5.3 Products
    • 9.5.4 Recent Developments
  • 9.6. LFB Biotechnologies
    • 9.6.1 Company Overview
    • 9.6.2 Company Revenue
    • 9.6.3 Products
    • 9.6.4 Recent Developments
  • 9.7. Grifols SA
    • 9.7.1 Company Overview
    • 9.7.2 Company Revenue
    • 9.7.3 Products
    • 9.7.4 Recent Developments
  • 9.8. CSL Behring
    • 9.8.1 Company Overview
    • 9.8.2 Company Revenue
    • 9.8.3 Products
    • 9.8.4 Recent Developments
  • 9.9. China Biologics Products Inc.
    • 9.9.1 Company Overview
    • 9.9.2 Company Revenue
    • 9.9.3 Products
    • 9.9.4 Recent Developments
  • 9.10. Kedrion Biopharma
    • 9.10.1 Company Overview
    • 9.10.2 Company Revenue
    • 9.10.3 Products
    • 9.10.4 Recent Developments
  • 9.11. BDI Pharma Inc
    • 9.11.1 Company Overview
    • 9.11.2 Company Revenue
    • 9.11.3 Products
    • 9.11.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies